Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: Mr. Giller who wrote (199)	1/3/1998 5:59:00 PM
From: Manny Gugliuzza	Read Replies (1) \| Respond to of 1510

sir, they will not be back in the office till monday am. if i do not get a response then i will start to hound. I am glad some else is still interested. usually there is some information every month updated, but they really need to address our concerns which are legitimate, in light of market pressure,cash flow,fda timetable, and current production costs to meet ongoing studies. anyone else want to add any thing i should ask within reason and not to revealing for a phone call? ar.

To: Mr. Giller who wrote (199)	1/5/1998 3:28:00 PM
From: Manny Gugliuzza	Read Replies (1) \| Respond to of 1510

and here it is folks>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> "the company currently has over 30 million in cash. we are currently in disscusions with several large pharmaceutical companies regarding partnerships in autoimmune disease and gene therapy and expect to enter into at least one arrangement during the first quarter 1998." debra altman. i am still checking into the use of remune for the veterinary profession. currently we are using the recombinant dna by schering corp. and immune regulin to aid the the immune system to help fight secondary infection after viral invasion. not sure about the fda timetable but any large corp. would not commit to partner without resonable assurance of this no? hope this helps here's to a great new year and a lot of promising results comming soon. ar.